Eli Lilly Weight-Loss Strategy vs Novo: Price War Shock
Can the Eli Lilly Weight-Loss Strategy stay on top as Novo Nordisk slashes prices and AI reshapes the obesity drug race? Maik Kemper Editor in Chief Conclusion In…
Eli Lilly Foundayo Soars +4.6% as GLP-1 Pill Bets Grow
Can Eli Lilly Foundayo and the Centessa deal push Lilly’s GLP-1 dominance into an even more powerful multi-drug growth story? Maik Kemper Editor in Chief As a convenient,…
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in GLP-1 leaders? Maik Kemper Editor in Chief The…
Hims & Hers Novo Nordisk deal sparks 44% premarket surge
Can the new Hims & Hers Novo Nordisk deal really turn an 80% stock collapse into a long-term GLP-1 comeback story? How big is the market reaction to…
Eli Lilly Investment -$37.70: Rally Warning for Bulls
Can the latest Eli Lilly Investment wave in GLP-1 plants and AI supercomputing still justify a trillion-dollar style valuation? How does the Eli Lilly Investment in Pennsylvania change…